214 related articles for article (PubMed ID: 30523696)
1. Skin adverse events in recently approved targeted therapies in solid malignancies.
Habre M; Salloum A; Habre SB; Abi Chebl J; Dib R; Kourie HR
Future Oncol; 2019 Jan; 15(3):331-343. PubMed ID: 30523696
[TBL] [Abstract][Full Text] [Related]
2. Dermatological side effects of current and upcoming targeted therapies in oncology.
Bonny M; Buyse V; Brochez L
Acta Clin Belg; 2011; 66(2):97-103. PubMed ID: 21630605
[TBL] [Abstract][Full Text] [Related]
3. Molecular targeted therapies for solid tumors: management of side effects.
Grünwald V; Soltau J; Ivanyi P; Rentschler J; Reuter C; Drevs J
Onkologie; 2009 Mar; 32(3):129-38. PubMed ID: 19295254
[TBL] [Abstract][Full Text] [Related]
4. Incidence and risk of xerosis with targeted anticancer therapies.
Valentine J; Belum VR; Duran J; Ciccolini K; Schindler K; Wu S; Lacouture ME
J Am Acad Dermatol; 2015 Apr; 72(4):656-67. PubMed ID: 25637330
[TBL] [Abstract][Full Text] [Related]
5. Skin moisturization for xerosis related to targeted anticancer therapies.
Gisondi P; Girolomoni G
J Am Acad Dermatol; 2015 Jul; 73(1):e33. PubMed ID: 26089072
[No Abstract] [Full Text] [Related]
6. Reply to: "Skin moisturization for xerosis related to targeted anticancer therapies".
Valentine J; Belum VR; Duran J; Ciccolini K; Schindler K; Wu S; Lacouture ME
J Am Acad Dermatol; 2015 Jul; 73(1):e35-6. PubMed ID: 26089073
[No Abstract] [Full Text] [Related]
7. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
8. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors.
Vigarios E; Epstein JB; Sibaud V
Support Care Cancer; 2017 May; 25(5):1713-1739. PubMed ID: 28224235
[TBL] [Abstract][Full Text] [Related]
9. Non-rash skin toxicities associated with novel targeted therapies.
Lacouture ME; Boerner SA; Lorusso PM
Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S36-42. PubMed ID: 17239289
[TBL] [Abstract][Full Text] [Related]
10. Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer.
Lacouture ME
Cancer Nurs; 2007; 30(4 Suppl 1):S17-26. PubMed ID: 17666987
[TBL] [Abstract][Full Text] [Related]
11. Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis.
Belum VR; Washington C; Pratilas CA; Sibaud V; Boralevi F; Lacouture ME
Pediatr Blood Cancer; 2015 May; 62(5):798-806. PubMed ID: 25683226
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous adverse reactions to therapeutic monoclonal antibodies for cancer.
Myskowski PL; Halpern AC
Curr Allergy Asthma Rep; 2008 Mar; 8(1):63-8. PubMed ID: 18377777
[TBL] [Abstract][Full Text] [Related]
13. Dermatologic Reactions to Targeted Therapy: A Focus on Epidermal Growth Factor Receptor Inhibitors and Nursing Care.
Barton-Burke M; Ciccolini K; Mekas M; Burke S
Nurs Clin North Am; 2017 Mar; 52(1):83-113. PubMed ID: 28189168
[TBL] [Abstract][Full Text] [Related]
14. Understanding Toxicities of Targeted Agents: Implications for Anti-tumor Activity and Management.
Liu S; Kurzrock R
Semin Oncol; 2015 Dec; 42(6):863-75. PubMed ID: 26615131
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous adverse effects of the immune checkpoint inhibitors.
Collins LK; Chapman MS; Carter JB; Samie FH
Curr Probl Cancer; 2017; 41(2):125-128. PubMed ID: 28190531
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapies for solid tumors: current status and future perspectives.
Stoffel A
BioDrugs; 2010 Oct; 24(5):303-16. PubMed ID: 20649180
[TBL] [Abstract][Full Text] [Related]
17. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
Wu PA; Balagula Y; Lacouture ME; Anadkat MJ
Curr Opin Oncol; 2011 Jul; 23(4):343-51. PubMed ID: 21537180
[TBL] [Abstract][Full Text] [Related]
18. Clinical research of EGFR inhibitors and related dermatologic toxicities.
Perez-Soler R; Van Cutsem E
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):10-6. PubMed ID: 18154213
[TBL] [Abstract][Full Text] [Related]
19. Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel.
Cury-Martins J; Eris APM; Abdalla CMZ; Silva GB; Moura VPT; Sanches JA
An Bras Dermatol; 2020; 95(2):221-237. PubMed ID: 32165025
[TBL] [Abstract][Full Text] [Related]
20. Review: side effects of approved molecular targeted therapies in solid cancers.
Widakowich C; de Castro G; de Azambuja E; Dinh P; Awada A
Oncologist; 2007 Dec; 12(12):1443-55. PubMed ID: 18165622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]